Article
Multidisciplinary Sciences
Babak Moghimi, Sakunthala Muthugounder, Samy Jambon, Rachelle Tibbetts, Long Hung, Hamid Bassiri, Michael D. Hogarty, David M. Barrett, Hiroyuki Shimada, Shahab Asgharzadeh
Summary: The study highlights the importance of developing gated systems for predicting clinical toxicity of CAR T cells in solid tumors. By utilizing murine and human CAR-T cells specific for tumor antigens, the researchers were able to generate a GD2-B7H3 CAR-T with improved metabolic fitness and efficacy in controlling neuroblastoma growth in preclinical models. This innovative approach shows promising results in suppressing neuroblastoma with minimal adverse effects.
NATURE COMMUNICATIONS
(2021)
Review
Pharmacology & Pharmacy
Pierre Machy, Erwan Mortier, Stephane Birkle
Summary: Ganglioside GD2, a complex glycolipid located on the cell membrane, exhibits diverse expression patterns and functions. Its overexpression in cancer enhances cell survival and invasion, while also contributing to T-cell dysfunction and functioning as an immune checkpoint. These cancer-associated functions make GD2 a potential target for immunotherapy.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Johanna Theruvath, Marie Menard, Benjamin A. H. Smith, Miles H. Linde, Garry L. Coles, Guillermo Nicolas Dalton, Wei Wu, Louise Kiru, Alberto Delaidelli, Elena Sotillo, John L. Silberstein, Anna C. Geraghty, Allison Banuelos, Molly Thomas Radosevich, Shaurya Dhingra, Sabine Heitzeneder, Aidan Tousley, John Lattin, Peng Xu, Jing Huang, Nicole Nasholm, Andy He, Tracy C. Kuo, Emma R. B. Sangalang, Jaume Pons, Amira Barkal, Rachel E. Brewer, Kristopher D. Marjon, Jose G. Vilches-Moure, Payton L. Marshall, Ricardo Fernandes, Michelle Monje, Jennifer R. Cochran, Poul H. Sorensen, Heike E. Daldrup-Link, Irving L. Weissman, Julien Sage, Ravindra Majeti, Carolyn R. Bertozzi, William A. Weiss, Crystal L. Mackall, Robbie G. Majzner
Summary: The combination of anti-GD2 and CD47 blockade demonstrates robust anti-tumor activity in mouse models, particularly effective against neuroblastoma, osteosarcoma, and small-cell lung cancer.
Article
Pediatrics
Michael Launspach, Marita Seif, Theresa M. Thole, Patrick Jesse, Joachim Schulz, Johannes H. Schulte, Susan Bischoff, Angelika Eggert, Hedwig E. Deubzer
Summary: This case report described the clinical course and management of dinutuximab beta extravasation in a 3-year-old child. The patient significantly improved after six days of treatment and fully recovered by day 20 with appropriate management strategies.
Article
Oncology
Felix Zirngibl, Sara M. Ivasko, Laura Grunewald, Anika Klaus, Silke Schwiebert, Peter Ruf, Horst Lindhofer, Kathy Astrahantseff, Lena Andersch, Johannes H. Schulte, Holger N. Lode, Angelika Eggert, Kathleen Anders, Patrick Hundsdoerfer, Annette Kuenkele
Summary: EKTOMUN and SUREK demonstrated promising efficacy against neuroblastoma, activating effector cells and tumor-infiltrating T cells, and showing significant control over neuroblastoma metastases.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Biochemistry & Molecular Biology
Enrico Rango, Fabio Pastorino, Chiara Brignole, Arianna Mancini, Federica Poggialini, Salvatore Di Maria, Claudio Zamperini, Giulia Iovenitti, Anna Lucia Fallacara, Samantha Sabetta, Letizia Clementi, Massimo Valoti, Silvia Schenone, Adriano Angelucci, Mirco Ponzoni, Elena Dreassi, Maurizio Botta
Summary: Si306, an anticancer agent, has shown favorable activity against neuroblastoma models. However, its sub-optimal aqueous solubility poses a limitation for its development. In this study, Si306 was encapsulated into liposomes and modified with an antibody specific for neuroblastoma cells. The modified liposomes demonstrated increased cellular targeting and cytotoxic activity. In animal experiments, Si306 encapsulated in targeted liposomes showed significantly higher tumor uptake and improved survival rates.
Article
Oncology
Aleksandra Wieczorek, Carla Manzitti, Alberto Garaventa, Juliet Gray, Vassilios Papadakis, Dominique Valteau-Couanet, Katarzyna Zachwieja, Ulrike Poetschger, Ingrid Pribill, Stefan Fiedler, Ruth Ladenstein, Holger N. Lode
Summary: This study reports on the incidence, clinical course, and management of neurotoxicity in patients treated with the anti-GD2 antibody dinutuximab beta, given with or without interleukin-2. Severe neurotoxic events were predominantly observed in patients receiving combined treatment with dinutuximab beta and interleukin-2, with most patients recovering following supportive management.
Article
Oncology
Marjolein C. Stip, Mitchell Evers, Maaike Nederend, Chilam Chan, Karli R. Reiding, Mirjam J. Damen, Albert J. R. Heck, Sofia Koustoulidou, Ruud Ramakers, Gerard C. Krijger, Remmert de Roos, Edouard Souteyrand, Annelisa M. Cornel, Miranda P. Dierselhuis, Marco Jansen, Mark de Boer, Thomas Valerius, Geert van Tetering, Jeanette H. W. Leusen, Friederike Meyer-Wentrup
Summary: Researchers engineered an antibody called IgA3.0 ch14.18, which shows promise as a new therapy for neuroblastoma. The antibody has a longer half-life, increased protein stability, and potent tumor-killing abilities.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Medical Laboratory Technology
Christine M. Busch, Frank M. Balis
Summary: This study establishes reference intervals for GD2 concentration in children within the age range where neuroblastoma commonly occurs. The concentration of GD2 is age-dependent and peaks at 6-12 months of age, which may reflect neurodevelopmental events.
CLINICAL BIOCHEMISTRY
(2022)
Article
Oncology
Nikolai Siebert, Justus Leopold, Maxi Zumpe, Sascha Troschke-Meurer, Simon Biskupski, Alexander Zikoridse, Holger N. Lode
Summary: Treatment with the anti-GD(2) antibody dinutuximab beta (DB) can improve the survival of high-risk neuroblastoma (NB) patients by 15%. In this study, a DB-based immunotherapy combined with the immunocytokine FAP-IL-2v was investigated as an alternative to IL-2 treatment. The combination therapy enhanced ADCC and reduced Treg cell induction, resulting in reduced tumor growth and improved survival in a murine NB model.
Review
Medicine, General & Internal
Ahmed Bassam Mohd, Omar B. Mohd, Yasmeen J. Alabdallat, Salem Yousef Al Dwairy, Reem A. Ghannam, Balqees M. Hanaqtah, Khaled A. Albakri
Summary: Dinutuximab, a monoclonal antibody targeting GD2 in neuroblastoma, has been found to improve survival in patients. It increases event-free survival and overall survival as maintenance therapy for high-risk neuroblastoma patients. However, the use of cytokines co-administered with Dinutuximab needs further research.
JOURNAL OF RESEARCH IN MEDICAL SCIENCES
(2023)
Article
Oncology
Stanley Ly, Vivek Anand, Fouad El-Dana, Khoa Nguyen, Yiming Cai, Shirong Cai, Helen Piwnica-Worms, Debasish Tripathy, Aysegul A. Sahin, Michael Andreeff, Venkata Lokesh Battula
Summary: GD2 is expressed in around 60% of primary TNBC tumors at variable levels and is associated with worse overall survival of patients with TNBC. Treatment with dinutuximab significantly decreased adhesion and migration of TNBC cells, inhibited mTOR signaling, and reduced tumor growth in both cell-line xenografts and PDX models. Our data provide proof-of-concept for the critical role of GD2 in BCSCs and demonstrate the potential of dinutuximab as a novel therapeutic approach for TNBC.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Biochemistry & Molecular Biology
Kwang-Hyeok Kim, Jin-Ock Kim, Jeong-Yang Park, Min-Duk Seo, Sang Gyu Park
Summary: Lung cancer is a major cause of cancer-related deaths, with small cell lung cancer (SCLC) accounting for a significant portion. Overexpression of c-Kit is a characteristic of SCLC. This study found that the antibody-drug conjugate 4C9-DM1 shows potential as a therapeutic agent for SCLC, as it efficiently induces apoptosis and inhibits tumor growth. Combination treatment with other drugs further enhances its anti-tumor effects.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Jaume Mora, Shakeel Modak, Joyce Kinsey, Carolyn E. Ragsdale, Hillard M. Lazarus
Summary: Colony-stimulating factors, such as GM-CSF, have been studied extensively for their potential to enhance the effectiveness of anti-GD2 monoclonal antibodies in high-risk neuroblastoma. However, access to these therapies is not uniform, and there is limited clinical data supporting the use of G-CSF as an alternative to GM-CSF. More research is needed to ensure equitable access to these treatments globally.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Engineering, Biomedical
Kimberly J. Ornell, Bill Chiu, Jeannine M. Coburn
Summary: The study investigates the use of silk fibroin as a delivery system for sustained local release of bioactive DNX, overcoming challenges of large size and dose-limiting side effects. It is found that the impact of silk properties on release properties and the bioactivity of the release product. Furthermore, the effectiveness of CDC induction by DNX may be correlated to the GD2 expression level of the target cells.
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
(2021)